Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13595284 | 1.00 | SLC6A2 (0.55) | SLC6A2SLC6A4TP53LMNAGAA | |
| SCHEMBL4084852 | 1.00 | SLC6A2 (0.55) | SLC6A2SLC6A4TP53LMNAGAA | |
| SCHEMBL4081240 | 1.00 | SLC6A2 (0.55) | SLC6A2SLC6A4TP53LMNAGAA | |
| Hydrochloric Acid SCHEMBL4077313 | 0.99 | SLC6A2 (0.55) | SLC6A2SLC6A4TP53LMNAGAA | |
| Hydrochloric Acid SCHEMBL4079856 | 0.99 | SLC6A2 (0.55) | SLC6A2SLC6A4TP53LMNAGAA | |
| Hydrochloric Acid SCHEMBL4076980 | 0.99 | SLC6A2 (0.55) | SLC6A2SLC6A4TP53LMNAGAA | |
| SCHEMBL4410546 | 0.89 | SLC6A2 (0.68) | SLC6A2SLC6A4 | |
| SCHEMBL4413645 | 0.89 | SLC6A2 (0.68) | SLC6A2SLC6A4 | |
| SCHEMBL4410002 | 0.88 | SLC6A2 (0.56) | SLC6A2SLC6A4MAPT | |
| SCHEMBL4410006 | 0.88 | SLC6A2 (0.56) | SLC6A2SLC6A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414052-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2008-08-19 | — | — | US | claimed |
| EP-1730127-B1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-06-25 | — | — | EP | claimed |
| EP-1730127-A1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth, A Corporation of the State of Delaware (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005097761-A1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050222142-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | claimed |
| US-7638512-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638512-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638512-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-7517899-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1732887-B1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1732887-B1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1732887-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1730127-A1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth, A Corporation of the State of Delaware (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005097744-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097761-A1 | HETEROCYCLIC PHENYLAMINOPROPANOL DERIVATIVES AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050222142-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | SLC6A2 8/4885SLC6A4 13/4885TP53 4041/4885 |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | PAH, PNMT, COMT | SLC6A2 8/4885SLC6A4 13/4885TP53 4041/4885 |
| US-20050222142-A1 | Phenylaminopropanol derivatives and methods of their use | PAH, PNMT, COMT | SLC6A2 8/4885SLC6A4 13/4885TP53 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.